All In Biotech

Drug Trial Radar · NCT07801027

A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)

A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Combination With Indication-specific Chemotherapy or Chemoradiotherapy in Participants Across Multiple Indications in India (KEYNOTE-G44)

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

Jan 31, 2030

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety of pembrolizumab with chemotherapy or chemoradiotherapy in participants in India for: * Advanced gastric or gastroesophageal junction \[GEJ\] cancer that is (human epidermal growth factor receptor 2 \[HER2\]-negative and has a programmed death-ligand 1 \[PD-L1\] combined positive score \[CPS\] ≥1 * Advanced and/or unresectable biliary tract cancer \[BTC\], and * High-risk, locally advanced cervical cancer

Conditions

  • Neoplasm Malignant
  • Gastric Neoplasms
  • Gastroesophageal Junction Adenocarcinoma
  • Biliary Tract Carcinoma
  • Uterine Cervical Neoplasms

Interventions

  • PembrolizumabBiological

    Administered as an IV infusion

  • CisplatinDrug

    Administered as an IV infusion

  • 5-FluorouracilDrug

    Administered as an IV infusion

  • OxaliplatinDrug

    Administered as an IV infusion

  • CapecitabineDrug

    Administered as an oral tablet

  • GemcitabineDrug

    Administered as an IV infusion

  • External Beam RadiotherapyRadiation

    External beam radiation per the Radiation Manual

  • BrachytherapyRadiation

    Internal radiation - brachytherapy per the Radiation Manual

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced One or More Adverse Events (AEs)Time frame: Up to approximately 27 months
  2. Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.